全文获取类型
收费全文 | 1409836篇 |
免费 | 115646篇 |
国内免费 | 3331篇 |
专业分类
耳鼻咽喉 | 18370篇 |
儿科学 | 46596篇 |
妇产科学 | 41091篇 |
基础医学 | 200876篇 |
口腔科学 | 37725篇 |
临床医学 | 126087篇 |
内科学 | 284623篇 |
皮肤病学 | 33422篇 |
神经病学 | 117000篇 |
特种医学 | 53913篇 |
外国民族医学 | 464篇 |
外科学 | 210654篇 |
综合类 | 32755篇 |
现状与发展 | 3篇 |
一般理论 | 487篇 |
预防医学 | 110046篇 |
眼科学 | 31505篇 |
药学 | 98610篇 |
1篇 | |
中国医学 | 3354篇 |
肿瘤学 | 81231篇 |
出版年
2021年 | 10871篇 |
2019年 | 11679篇 |
2018年 | 16606篇 |
2017年 | 12694篇 |
2016年 | 14280篇 |
2015年 | 16031篇 |
2014年 | 22599篇 |
2013年 | 33421篇 |
2012年 | 45464篇 |
2011年 | 48005篇 |
2010年 | 28206篇 |
2009年 | 27098篇 |
2008年 | 44399篇 |
2007年 | 46881篇 |
2006年 | 47443篇 |
2005年 | 45894篇 |
2004年 | 43814篇 |
2003年 | 41742篇 |
2002年 | 40236篇 |
2001年 | 73042篇 |
2000年 | 74561篇 |
1999年 | 61585篇 |
1998年 | 16998篇 |
1997年 | 15440篇 |
1996年 | 15593篇 |
1995年 | 14802篇 |
1994年 | 13400篇 |
1993年 | 12591篇 |
1992年 | 45856篇 |
1991年 | 43493篇 |
1990年 | 41505篇 |
1989年 | 39564篇 |
1988年 | 36203篇 |
1987年 | 35366篇 |
1986年 | 32872篇 |
1985年 | 31288篇 |
1984年 | 23835篇 |
1983年 | 20029篇 |
1982年 | 12210篇 |
1981年 | 10788篇 |
1979年 | 20703篇 |
1978年 | 14581篇 |
1977年 | 12085篇 |
1976年 | 11371篇 |
1975年 | 11623篇 |
1974年 | 13994篇 |
1973年 | 13537篇 |
1972年 | 12643篇 |
1971年 | 11478篇 |
1970年 | 10918篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
951.
952.
953.
K Thomsen B J Riis J S Johansen C Christiansen P R?dbro 《Gynecological endocrinology》1987,1(2):169-175
Bone turnover before and after withdrawal of estrogen/gestagen treatment was studied in a randomized trial with 110 healthy female volunteers, who had passed a natural menopause 6 months to 3 years before the start of the study. Urinary excretion of intravenously injected 99m-technetium diphosphonate was measured as an index of bone turnover; plasma bone Gla protein and serum alkaline phosphatase were measured as indices of bone formation; and fasting urinary excretion of hydroxyproline and calcium were measured as estimates of bone resorption. During 2 years of hormone treatment, all variables decreased highly significantly (p less than 0.001) to a constant low level. Three months after withdrawal all variables increased highly significantly (p less than 0.001) towards, but not above, pretreatment and placebo levels. We conclude that withdrawal of estrogen/gestagen replacement therapy in postmenopausal women increases bone turnover, but not in excess of pretreatment values. This indicates that bone loss (after withdrawal) is similar to that seen in the placebo group and that a rebound phenomenon is unlikely. 相似文献
954.
P M A van Haaren H P Kok C A T van den Berg P J Zum V?rde Sive V?rding S Oldenborg L J A Stalpers M S Schilthuis A A C de Leeuw J Crezee 《International journal of hyperthermia》2007,23(3):303-314
PURPOSE: The aim of this study was to verify hyperthermia treatment planning calculations by means of measurements performed during hyperthermia treatments. The calculated specific absorption rate (SAR(calc)) was compared with clinically measured SAR values, during 11 treatments in seven cervical carcinoma patients. METHODS: Hyperthermia treatments were performed using the 70 MHz AMC-4 waveguide system. Temperatures were measured using multisensor thermocouple probes. One invasive thermometry catheter in the cervical tumour and two non-invasive catheters in the vagina were used. For optimal tissue contact and fixation of the catheters, a gynaecological tampon was inserted, moisturized with distilled water (4 treatments), or saline (6 treatments) for better thermal contact. During one treatment no tampon was used. At the start of treatment the temperature rise (DeltaT(meas)) after a short power pulse was measured, which is proportional to SAR(meas). The SAR(calc) along the catheter tracks was extracted from the calculated SAR distribution and compared with the DeltaT(meas)-profiles. RESULTS: The correlation between DeltaT(meas) and SAR(calc) was on average R = 0.56 +/- 0.28, but appeared highly dependent on the wetness of the tampon (preferably with saline) and the tissue contact of the catheters. Correlations were strong (R approximately 0.85-0.93) when thermal contact was good, but much weaker (R approximately 0.14-0.48) for cases with poor thermal contact. CONCLUSION: Good correlations between measurements and calculations were found when tissue contact of the catheters was good. The main difficulties for accurate verification were of clinical nature, arising from improper use of the gynaecological tampon. Poor thermal contact between thermocouples and tissue caused measurement artefacts that were difficult to correlate with calculations. 相似文献
955.
A R Dias R N Melo O C E Gebara E A D'Amico A Nussbacher H W Halbe J A Pinotti 《Climacteric》2005,8(1):63-70
OBJECTIVES: To compare the effect of conjugated equine estrogens (CEE) and raloxifene on lipid profile and hemostasis. MATERIALS AND METHODS: A double-blind, randomized and parallel study was performed with 90 healthy postmenopausal women, aged 54 +/- 5 years, divided into three groups and submitted to daily therapy with either CEE 0.625 mg, raloxifene 60 mg or placebo for 4 months. The lipid profile, coagulation and fibrinolytic factors were analyzed. RESULTS: CEE increased the levels of high density lipoprotein cholesterol (HDL-C) from 49.0 to 56.8 mg/dl (p < 0.001), very low density lipoprotein cholesterol (VLDL-C) from 17.2 to 22.3 mg/dl (p < 0.001), and triglycerides from 86.0 to 111.7 mg/dl (p < 0.001), and decreased the levels of low density lipoprotein cholesterol (LDL-C) from 121.0 to 106.5 mg/dl (p < 0.001). The only significant effect of raloxifene was an increase in the levels of HDL-C from 46.0 to 47.8 mg/dl (p = 0.019). There was no significant reduction in LDL-C, from 115.5 to 110.2 mg/dl (p = 0.06), VLDL-C, from 21.7 to 20.0 mg/dl (p = 0.201), and triglycerides, from 108 to 100 mg/dl (p = 0.201). CEE decreased the levels of fibrinogen, from 370.5 to 326.8 g/l (p = 0.039) and the levels of antithrombin III, from 99.5 to 93.2% (p < 0.001). Raloxifene decreased the levels of fibrinogen, from 354.7 to 302.0 g/l (p = 0.009) and the levels of antithrombin III, from 102.4 to 98.5% (p = 0.039). CEE increased levels of protein C from 103.7 to 115.3 mg/l (p < 0.001) and raloxifene did not change the levels of protein C (107.9 to 105.1 mg/l; p = 0.158). CEE decreased the antigen levels of tissue plasminogen activator (t-PA) from 8.8 to 6.8 U/ml (p < 0.001), and of plasminogen activator inhibitor (PAI-1) from 30.8 to 21.6 U/ml (p < 0.010), whereas raloxifene had no significant effect on either t-PA, from 9.6 to 9.2 U/ml (p = 0.235) or PAI-1 antigen levels, from 32.1 to 30.4 U/ml (p = 0.538). CONCLUSION Both CEE and raloxifene exert significant effects on the lipid and coagulation profile. CEE had a more significant effect on fibrinolysis than raloxifene. These effects may have a significant impact on the cardiovascular risk that needs to be confirmed in larger studies. 相似文献
956.
Haloperidol is a receptor D2 antagonist frequently used in the treatment of schizophrenic patients. Haloperidol increased prolactin release from anterior pituitary gland, and prolactin modulates immune system activity. Groups of six male and female rats received an acute 2 mg/kg haloperidol treatment (E1), or a long-term (E2) haloperidol treatments (2 mg/kg/day for 21 days); control rats were treated similarly, but with control solution (groups C1 and C2, respectively). In this work long-term haloperidol treatment (E2) increased macrophage spreading, phagocytosis and NO release in male and female rats. However, acute haloperidol treatment (E1) did not change macrophage activity. Corticosterone and prolactin serum levels were increased after acute (E1) and long-term (E2) haloperidol treatments in male and female rats, being this increment higher in female. Macrophage of male and female rats presented the same pattern of alterations after acute and long-term haloperidol treatments. Haloperidol-induced macrophage activation was discussed in the light of a possible indirect effect through prolactin increments in rats, or, alternatively, as a consequence of a direct action of macrophage dopamine receptor. 相似文献
957.
I Kandarakis D Cavouras D Nikolopoulos A Episkopakis N Kalivas P Liaparinos I Valais G Kagadis K Kourkoutas I Sianoudis N Dimitropoulos C Nomicos G Panayiotakis 《Applied radiation and isotopes》2006,64(4):508-519
The aim of this study was to examine the angular distribution of the light emitted from radiation-excited scintillators in medical imaging detectors. This distribution diverges from Lambert's cosine law and affects the light emission efficiency of scintillators, hence it also affects the dose burden to the patient. In the present study, the angular distribution was theoretically modeled and was used to fit experimental data on various scintillator materials. Results of calculations revealed that the angular distribution is more directional than that predicted by Lambert's law. Divergence from this law is more pronounced for high values of light attenuation coefficient and thick scintillator layers (screens). This type of divergence reduces light emission efficiency and hence it increases the incident X-ray flux required for a given level of image brightness. 相似文献
958.
959.
960.
C. Fischer W. Gross J. Krüger M. Cremer F. Vogel T. Grimm 《Annals of human genetics》2006,70(2):237-248
For several genetic diseases two biological phenomena have been recognised as important: germline mosaicism; and different new mutation rates in males and females depending on mutation type. Both principles have been investigated separately and their influence on risk estimation in families has been exemplified in the literature. The aim of this paper is to present a general model that includes mosaicism and different new mutation rates. Mosaicism is introduced by defining additional alleles at the disease locus in combination with adapted segregation rules. Taking Duchenne muscular dystrophy as an example, we derive the conditions which have to be fulfilled for a population in mutation selection equilibrium. Our approach describes the model at the population level and not in individual subjects. This has the advantage of being able to use well known algorithms for the calculation of likelihoods in pedigrees, and to include additional diagnostic information such as marker genotypes and carrier deletion test results. We demonstrate the impact of the new model on a typical pedigree. In families where the patient is not available, the distinction between point mutations and deletions is important, since often molecular diagnostic tests for females can only screen for deletions. Negative deletion test results can now be included in the risk calculations. 相似文献